Publications by authors named "Monika Swierczynska"

Pulmonary emphysema is anatomically defined as abnormal persistent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls, without evident fibrosis. High-resolution computer tomography (HRCT) imaging is a valuable tool for diagnosis of this disease. The presence of minute cysts distributed evenly through all lung zones is rarely observed in pulmonary emphysema.

View Article and Find Full Text PDF

Unlabelled: Surgical treatment of bilateral vocal fold paralysis must be undertaken if such a condition lasts 6-12 months or longer and causes dyspnoea. The purpose of the procedures is to assure proper airflow through the glottis and to preserve good voice and unimpaired swallowing. Modern endoscopic surgery of the glottis is performed with CO2 laser.

View Article and Find Full Text PDF

We describe a case of a 52-year old woman with clinical and immunological features of sicca syndrome associated with pulmonary fibrosis, anti-Jo-1, and anti-Ro-52 antibodies but without any signs of idiopathic inflammatory myopathy.

View Article and Find Full Text PDF

Background: Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins. The basal and postchallenge levels of eicosanoids might reflect the clinical and biochemical characteristics of patients with distinct types of hypersensitive responses to aspirin.

Objective: We compared clinical and eicosanoid profiles of patients with AIAR showing both bronchial and nasal versus isolated nasal responses to aspirin challenge.

View Article and Find Full Text PDF

The aim of our article was to present the actual state of knowledge of the non-allergic rhinitis with eosinophilia syndrome (NARES). NARES is characterized by perennial rhinitis and nasal eosinophilia in the absence of allergy in patient's history, negative skin tests and normal IgE. This syndrome was described 20 years ago, but studies on it are scarce.

View Article and Find Full Text PDF

Asacard is a microcapsulated, controlled-release form of acetylsalicylic acid, which delivers very low but constant amount of the drug directly into the intestine. The dose 162.5 mg Asacard, used in prevention of cardiovascular diseases, is thus sufficient to block platelets in the portal vein from synthesizing thromboxane but not high enough to enter the systemic circulation and block the formulation of prostacyclin and other prostaglandins.

View Article and Find Full Text PDF